Daily fever, falling platelets, and a ferritin of 4,800: systemic JIA evolving into MAS
An 18-month-old boy is admitted with 12 days of daily fever to 39.5°C, an evanescent salmon-colored rash, and refusal to bear weight. Two antibiotic courses have not helped. On hospital day 3 he is irritable and tachycardic. CRP is 190 mg/L, ESR 108 mm/h (down from 120), ferritin 4,800 ng/mL, platelets 74,000/µL (down from 310,000), fibrinogen 110 mg/dL, triglycerides 310 mg/dL, ALT 165 U/L, and D-dimer is elevated. Blood and urine cultures are negative. Echocardiography shows no coronary dilation. Both wrists and the left knee are swollen. The family lives 4 hours away and asks whether he can be transferred to a local hospital once the fever settles.
1. What is the leading diagnosis, and which findings change your immediate management? Show your reasoning.
Read the worked answer
Daily fever for more than 10 days, an evanescent rash, and arthritis point to systemic JIA; negative cultures and normal coronaries argue against sepsis and Kawasaki disease. The decisive features are the falling platelet count and ESR despite a high CRP, fibrinogen 110 mg/dL, ferritin 4,800, triglycerides 310, and transaminitis. This is macrophage activation syndrome (MAS), not merely active sJIA. A falling ESR is not reassuring-it reflects fibrinogen consumption.
Do not transfer him; MAS can decompensate within hours. Start pulse IV methylprednisolone (30 mg/kg/day for 3 days), anakinra 2–4 mg/kg/day (higher if refractory), and consider cyclosporine. Continue broad-spectrum antibiotics until cultures are final. Monitor CBC, fibrinogen, ferritin, triglycerides, and liver enzymes every 12 hours, and watch for DIC and CNS dysfunction.
2. After 48 hours the fever persists and ferritin rises to 6,000 ng/mL. How do you escalate, and why is tocilizumab a poor rescue choice?
Read the worked answer
Persistent fever plus rising ferritin means the cytokine storm is not controlled. Escalate IL-1 blockade (anakinra to 5–10 mg/kg/day or switch to canakinumab), add cyclosporine, and if there is progressive cytopenia, hypofibrinogenemia, or CNS involvement, move to HLH-directed therapy with dexamethasone and etoposide. Re-culture and examine for a focal infection, because infection can trigger MAS.
Tocilizumab is a poor rescue choice because IL-6 blockade can suppress fever and CRP while MAS continues; it also does not target the IL-1/IL-18 axis driving the syndrome. Avoid NSAIDs given hepatopathy and renal risk. Involve pediatric critical care early. The 12-hour trajectory of ferritin, fibrinogen, and platelets matters more than any single value.
3. At discharge the parents ask about a monthly injection and about vaccinations. How do you choose maintenance therapy and counsel them?
Read the worked answer
Once fever, ferritin, and fibrinogen have normalized, choose a long-acting IL-1 blocker-canakinumab every 4 weeks, or continued daily anakinra if the family can manage injections. Tocilizumab is an alternative but is less attractive after MAS. Before starting, screen for latent TB (IGRA and chest radiograph) and hepatitis B, and update inactivated vaccines.
Live vaccines (MMR, varicella) are contraindicated on high-dose corticosteroids or biologics; document and defer. Explain that a missed canakinumab dose can precipitate relapse, and that fever with rash requires same-day labs rather than telephone reassurance. Give a written emergency plan naming MAS as the concern so outside clinicians do not treat him as a viral illness.